Grifols SA

GRFS · XNAS

CIK 1438569fmd_0R5GEYNKRNJ6ANESRQH4WBHMRTManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2015 to Dec 31, 2024, 10 periods

Income Statement · Annual · Millions · EUR
Line item	FY2015	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024
Total revenues	3,935	4,050	4,318	4,487	5,099	5,340	4,933	6,064	6,592	7,212
Cost of revenue	2,004	2,138	2,166	2,437	2,757	3,085	2,971	3,850	4,108	4,418
Gross profit	1,931	1,912	2,152	2,050	2,341	2,255	1,963	2,214	2,483	2,795
Research and development	224	198	288	241	276	294	355	361	395	384
Selling, general and administrative	736	775	860	815	943	986	1,062	1,196	1,373	1,255
Operating income	970	939	1,003	994	1,131	996	595	782	782	1,192
Interest expense	240	245	263	293	343	250	268	478	597	715
Income before taxes	690	713	696	726	817	879	350	338	207	444
Income tax expense	159	168	34	131	168	170	85	90	43	231
Net income from continuing operations	531	545	661	594	649	709	265	271	181	213
Net income	532	545	663	597	625	619	189	185	42	157
Net income to common shareholders	532	545	663	597	625	619	189	185	42	157